This program seeks to make Dr. Convit’s breast cancer immunotherapy a standard low cost treatment option for patients. Through partnerships with research and health centers, JCWO works to advance its clinical trials in the US, South America and Europe using the ConvitVax. Additionally, this program looks to further enhance the anti-tumor effect of the ConvitVax by testing it in combination with other breast cancer therapies, as well as evaluate it as a treatment for other types of malignant solid tumors. With this program we direct our efforts to develop accessible immunotherapy protocols that can be affordable for underprivileged patients who lack the possibility of entering new innovative treatments.
We aim to make this immunotherapy available to patients who do not have access to new innovative therapies and in some cases, to standard of care treatments.
Every day we continue writing a new page, know our most outstanding milestones in Cancer Immunotherapy
Dr. Convit, as a recently graduated medical doctor, starts to study Leprosy, also known as Hansen’s disease. He studied and documented detailed descriptions of the development of the disease and the lesions in patients that were confined in the leprosarium of Cabo Blanco in the city of La Guaira, in Venezuela. Dr. Convit lived with the patients in Cabo Blanco for more than 10 years, which gave him the advantage to learn much more about all aspects of the disease and be able to better treat the patients. His main goal was to eliminate the compulsory restraint of leprosy patients.